NexImmune (NEXI)
(Delayed Data from NSDQ)
$3.37 USD
-0.04 (-1.17%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $3.37 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
NEXI 3.37 -0.04(-1.17%)
Will NEXI be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for NEXI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NEXI
What Makes NexImmune, Inc. (NEXI) a New Buy Stock
Biotech Stock Roundup: APLS, NVAX Gain on Updates, INCYs Regulatory News & More
NEXI: What are Zacks experts saying now?
Zacks Private Portfolio Services
NexImmune (NEXI) IND Gets Clearance for HPV-Related Cancer Drug
What Makes NexImmune, Inc. (NEXI) a New Buy Stock
Other News for NEXI
NEXI Stock Earnings: NexImmune Reported Results for Q4 2023
GLOBAL BROKER RATINGS: JPMorgan raises Persimmon, BoA raises Nike
Analysts Offer Insights on Technology Companies: Solutions 30 SE (30L3) and Nexi S.p.A. (Milan: IT:NEXI)
NexImmune Announces Leadership Shift in Financial Management
XXII, GRIN and XTIA are among mid-day movers